Eric Dube's most recent trade in Travere Therapeutics Inc was a trade of 18,924 Common Stock done . Disclosure was reported to the exchange on May 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 18,924 | 438,097 (1%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 18,924 | 18,924 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 02 May 2025 | 18,924 | 419,173 (0%) | 0% | 21.0 | 398,350 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 24.04 per share. | 11 Feb 2025 | 11,375 | 419,173 (0%) | 0% | 24.0 | 273,455 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 260,000 | 260,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 130,000 | 481,239 (1%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 20.21 per share. | 31 Jan 2025 | 50,691 | 430,548 (0%) | 0% | 20.2 | 1,024,343 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 22 Jan 2025 | 10,736 | 351,239 (0%) | 0% | 19.5 | 208,923 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 32,500 | 383,100 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 05 Sep 2024 | 21,125 | 361,975 (0%) | 0% | 11.5 | 243,360 | Common Stock |
| Travere Therapeutics Inc | Dube Eric M. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 360,000 | 360,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 135,000 | 369,722 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | M. Dube Eric | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 8.86 per share. | 31 Jan 2024 | 10,016 | 350,600 (0%) | 0% | 8.9 | 88,742 | Common Stock |
| Travere Therapeutics Inc | Dube M. Eric | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 9,106 | 360,616 (0%) | 0% | 8.5 | 77,693 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 8.96 per share. | 23 Jan 2024 | 7,873 | 234,722 (0%) | 0% | 9.0 | 70,542 | Common Stock |
| Reneo Pharmaceuticals Inc | Eric M. Dube | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 260,000 | 260,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 97,500 | 245,346 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 32,500 | 32,500 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.25 per share. | 31 Jan 2023 | 8,196 | 237,150 (0%) | 0% | 22.3 | 182,361 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 24 Jan 2023 | 6,442 | 147,846 (0%) | 0% | 21.5 | 138,503 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.75 per share. | 05 Jan 2023 | 5,625 | 154,288 (0%) | 0% | 20.8 | 116,719 | Common Stock |
| Reneo Pharmaceuticals Inc | Eric Dube | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.84 per share. | 10 Feb 2022 | 4,832 | 159,913 (0%) | 0% | 27.8 | 134,523 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 169,552 | 169,552 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 37,848 | 37,848 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 37,848 | 169,558 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 31 Jan 2022 | 4,813 | 164,745 (0%) | 0% | 27.4 | 131,876 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.98 per share. | 24 Jan 2022 | 7,873 | 131,710 (0%) | 0% | 25.0 | 196,668 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.84 per share. | 04 Jan 2022 | 10,361 | 141,722 (0%) | 0% | 29.8 | 309,172 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 04 Jan 2022 | 4,832 | 152,083 (0%) | 0% | 30.4 | 147,038 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.48 per share. | 04 Jan 2022 | 2,139 | 139,583 (0%) | 0% | 30.5 | 65,197 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 17,500 | 164,751 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.12 per share. | 13 Aug 2021 | 7,836 | 156,915 (0%) | 0% | 17.1 | 134,142 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.89 per share. | 01 Jun 2021 | 4,782 | 152,031 (0%) | 0% | 14.9 | 71,204 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.35 per share. | 01 Jun 2021 | 4,780 | 147,251 (0%) | 0% | 14.4 | 68,593 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.58 per share. | 05 Feb 2021 | 4,813 | 156,813 (0%) | 0% | 31.6 | 151,995 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.41 per share. | 05 Feb 2021 | 4,813 | 161,626 (0%) | 0% | 31.4 | 151,176 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 17,500 | 166,439 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 03 Feb 2021 | 2,406 | 148,939 (0%) | 0% | 28.9 | 69,557 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 15,000 | 160,079 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.60 per share. | 31 Jan 2021 | 6,328 | 153,751 (0%) | 0% | 29.6 | 187,282 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 31 Jan 2021 | 2,406 | 151,345 (0%) | 0% | 30.8 | 73,985 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 212,660 | 212,660 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.65 per share. | 05 Jan 2021 | 3,438 | 91,257 (0%) | 0% | 26.7 | 91,623 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 05 Jan 2021 | 3,438 | 87,819 (0%) | 0% | 27.0 | 92,860 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2020 | 25,000 | 102,500 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.28 per share. | 18 Sep 2020 | 9,240 | 96,260 (0%) | 0% | 19.3 | 178,133 | Common Stock |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2020 | 3,000 | 105,500 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.29 per share. | 18 Sep 2020 | 1,565 | 94,695 (0%) | 0% | 19.3 | 30,186 | Common Stock |